Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT5A | Q9NQR1 | 17/20 | 0.63 |
| ▸ | WHR1 | P49842 | 1/20 | 0.57 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.55 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25362090 | 1.00 | KMT5A (0.63) | KMT5AWHR1EHMT2EHMT1 | |
| SCHEMBL26639341 | 1.00 | KMT5A (0.63) | KMT5AWHR1EHMT2EHMT1 | |
| SCHEMBL25430396 | 0.95 | EHMT2 (0.62) | KMT5AWHR1EHMT2EHMT1 | |
| SCHEMBL30546999 | 0.95 | EHMT2 (0.62) | KMT5AWHR1EHMT2EHMT1 | |
| SCHEMBL25359230 | 0.95 | EHMT2 (0.62) | KMT5AWHR1EHMT2EHMT1 | |
| SCHEMBL25431583 | 0.92 | KMT5A (0.67) | KMT5AWHR1EHMT2EHMT1 | |
| SCHEMBL25363099 | 0.92 | KMT5A (0.67) | KMT5AWHR1EHMT2EHMT1 | |
| SCHEMBL25361574 | 0.92 | KMT5A (0.64) | KMT5AWHR1EHMT2EHMT1 | |
| SCHEMBL25432549 | 0.92 | KMT5A (0.64) | KMT5AWHR1EHMT2EHMT1 | |
| SCHEMBL25360678 | 0.91 | KMT5A (0.53) | KMT5AWHR1EHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630531-B2 | Quinazoline-2,4-diamine derivative and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | OMIC SMAP INC. (KR) | 2026-05-19 | — | — | US | disclosed |
| US-20230365530-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | OMIC SMAP INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| EP-4230624-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | The Asan Foundation (KR) | 2023-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630531-B2 | Quinazoline-2,4-diamine derivative and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | EHMT2, EHMT1, HNMT | KMT5A 13/4885WHR1 996/4885EHMT2 1/4885 |
| US-20230365530-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | EHMT2, EHMT1, HNMT | KMT5A 5/4885WHR1 752/4885EHMT2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.